Trial Profile
Evaluation of Cobimetinib + Vemurafenib Combination Treatment in Patients With Brain Metastasis BRAFV600 Mutated Cutaneous Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cobimetinib (Primary) ; Vemurafenib (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Therapeutic Use
- Acronyms CONVERCE
- 23 Jan 2020 Status changed from active, no longer recruiting to completed.
- 16 Jan 2019 Planned End Date changed from 1 Jun 2020 to 1 Nov 2020.
- 16 Jan 2019 Planned primary completion date changed from 1 Feb 2019 to 1 Nov 2019.